4.7 Article

Stochastic modulation evidences a transitory EGF-Ras-ERK MAPK activity induced by PRMT5

Journal

COMPUTERS IN BIOLOGY AND MEDICINE
Volume 133, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.compbiomed.2021.104339

Keywords

Cell response modulation; Cancer; MAPK pathway; EGF-Ras-ERK signaling Route; PRMT5; Methylation; Computational model

Funding

  1. MICINN [SAF2016-75246R, RTI2018097038BC22, BES2011043331]
  2. Generalitat de Catalunya (ICREA Academia) [2017 SGR 1015]
  3. CIBERDEM
  4. MICINN through the Centres of Excellence Severo Ochoa Award [CEX2018000789S, CEX 2019000913S]
  5. CERCA Programme of the Generalitat de Catalunya

Ask authors/readers for more resources

PRMT5 modulates the MAPK pathway by methylating Raf kinase, reducing the activation of ERK in time and amplitude, thereby avoiding aberrant behavior.
The extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway involves a three-step cascade of kinases that transduce signals and promote processes such as cell growth, development, and apoptosis. An aberrant response of this pathway is related to the proliferation of cell diseases and tumors. By using simulation modeling, we document that the protein arginine methyltransferase 5 (PRMT5) modulates the MAPK pathway and thus avoids an aberrant behavior. PRMT5 methylates the Raf kinase, reducing its catalytic activity and thereby, reducing the activation of ERK in time and amplitude. Two minimal computational models of the epidermal growth factor (EGF)-Ras-ERK MAPK pathway influenced by PRMT5 were proposed: a first model in which PRMT5 is activated by EGF and a second one in which PRMT5 is stimulated by the cascade response. The reported results show that PRMT5 reduces the time duration and the expression of the activated ERK in both cases, but only in the first model PRMT5 limits the EGF range that generates an ERK activation. Based on our data, we propose the protein PRMT5 as a regulatory factor to develop strategies to fight against an excessive activity of the MAPK pathway, which could be of use in chronic diseases and cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available